Member Info for TrickyEFC

And another 5 million buy.

Nice action ahaa

I know but 15 buys for every selling so far this morning.

They can't keep this down anylonger

Dv I am going to say you need to make a new prediction.

Buying is off its tits is it not

Dv how this is still showing red I can't fathom

Rather insane buying so far

10 buys for evey sell so far.

Its all about the 4s now lol

Bo and jbt nice one for the links. yep word is deffo getting out

10% of yesterdays volume in 10 mins.

mmmm

Very nice start indeed. hungry folk about

...

I dv fook the government hopefully and make dollar up in here.

Here to a blue blue day all.

Who said 35 sounds lovely

Sorry Llama with no debt plus 200mil.

Here's to a good day all.

As for reeves how many people with less than 20k in savings accounts would move to stocks n shares. Silly reasoning.

the mafia must be in awe. what a bunch of ****s they all are

mortgage costs will surge under rachel reeves's plan to cut the tax-free cash isa allowance, britain's largest lenders have warned. the chancellor is considering lowering the amount of money that savers can put into a cash isa without paying tax from the current rate of £20,000 to as low as £5,000. - telegraph

What is a Pharma worth with no debt, fully funded on a phase 3 trial that is with the NHS who have stated it will be taken up as soon as it is approved? And a Phase 2 with the FDA

80million?

If the in vitro Data for svns 14 is good then vore blimey we will be flying

Away from AUD products it's a big big month here.

Preclinical animal testing.

Awakn has previously announced successful preclinical animal testing results for one of the three synthesised candidates. The study demonstrated promising early signs of efficacy, supporting the potential of AWKN-SDN-14 as a next-generation PTSD treatment. These results provide a strong scientific foundation for the next phase of testing.

7. Lead candidate selection.

Following the completion of all preclinical screening, the Company expects to select a lead candidate by the end of Q3 2025, with a view to complete the sixth and final phase of the Programme.

Conclusion

Solvonis and Awakn remain fully committed to advancing the Programme and are encouraged by the progress achieved to date. With Concept resuming synthesis and Evotec engaged for key preclinical testing, the Programme remains on track to meet its revised milestones.

Further updates will be provided as the Programme progresses.

Not long to wait on the in-vitro dataToday 07:19

5. In-vitro screening for SERT, DAT, and NET release - Evotec appointed by Awakn to lead key preclinical testing.

To ensure the highest standard of preclinical validation, Awakn has appointed Evotec, a globally recognised leader in drug discovery and development, to conduct in-vitro screening for SERT, DAT, and NET release activity.

Evotec brings world-class expertise in:

· Neurotransmitter pharmacology

· High-throughput screening

· Precision drug discovery

Evotec's analysis will provide critical insights into the candidates' ability to modulate neurotransmitter release, a key mechanism underpinning AWKN-SDN-14's therapeutic potential.

This in-vitro testing phase, which builds on the positive animal testing results, is expected to be completed by the end of July 2025, aligning with the revised Programme timeline

Morning vinyl and co

Good posts again and have just used the filter button for 1st time.

Chop chops away

No RNs that this week. Be nice for that to change